Please wait while we open this resource.
K
Clinical reviews
LOW DOSE RIVAROXABAN FOR THE MANAGEMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
Placido Maria Mazzone, Davide Capodanno
PDF202312 pages940 KB
Atherosclerotic cardiovascular disease presents a risk of major adverse events despite effective therapies for secondary prevention. The document explores the role of thrombin in this residual risk and the advantages of using direct oral anticoagulants like rivaroxaban, particularly at lower doses. It reviews current guidelines recommending low-dose rivaroxaban for patients with stable atherosclerosis and acute coronary syndromes who are at low bleeding risk. Ongoing trials are also mentioned, focusing on various patient populations and clinical scenarios.
Sign in to open
Ask this resource
Answers use this document only.
Your first question is free.
More like this
Resources from the same specialty and type. Curated links will replace these when added.
Clinical Resources
Documents that extend or complement this resource.
SURVIVAL AFTER INITIAL STRESS TESTING VS ANATOMIC TESTING IN SUSPECTED CORONARY ARTERY DISEASE
Same clinical topic · Cardiology
PRACTICAL CARDIO-ONCOLOGY
Same clinical topic · Cardiology
OXFORD CARDIOLOGY LIBRARY: Hypertension
Same clinical topic · Cardiology
CARDIAC INVOLVEMENT IN PARASITIC INFECTIONS
Same clinical topic · Cardiology
The Athlete’s ECG
Same clinical topic · Cardiology
Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review
Same clinical topic · Cardiology
Current ECG Aspects of Interatrial Block
Same clinical topic · Cardiology
Arrhythmic mitral valve prolapse in 2023: Evidence-based update
Same clinical topic · Cardiology
INTERPRETING THE NORMAL PACEMAKER
Same clinical topic · Cardiology